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The aberrant misfolding and subsequent conversion of mono-
meric protein into amyloid aggregates characterises many
neurodegenerative disorders, including Parkinson’s and Alz-
heimer’s diseases. These aggregates are highly heterogeneous
in structure, generally of low abundance and typically smaller
than the diffraction limit of light (&250 nm). To overcome the
challenges these characteristics pose to the study of endoge-
nous aggregates formed in cells, we have developed a method
to characterise them at the nanometre scale without the need
for a conjugated fluorophore. Using a combination of DNA
PAINT and an amyloid-specific aptamer, we demonstrate that
this technique is able to detect and super-resolve a range of
aggregated species, including those formed by a-synuclein
and amyloid-b. Additionally, this method enables endogenous
protein aggregates within cells to be characterised. We found
that neuronal cells derived from patients with Parkinson’s dis-
ease contain a larger number of protein aggregates than those
from healthy controls.
Protein misfolding and aggregation is closely associated with
the development of many neurodegenerative disorders, such
as Alzheimer’s disease (AD) and Parkinson’s disease (PD).[1] In
AD, the protein tau is deposited in intracellular inclusions,[2]
while the amyloid beta (Ab) peptide is in extracellular plaques.
Similarly, in PD, aggregates of the protein a-synuclein (aS) are
found in Lewy bodies[3] within neuronal cells. These proteins
are often heavily post-translationally modified, for example, aS
undergoes phosphorylation, nitration and truncation,[4–6] this
makes it important to be able to characterise the real endoge-
nous aggregates formed in cells, as these can differ from those
formed by unmodified proteins.
Soluble nanometre-sized protein oligomers have been iden-
tified as the major cytotoxic species in AD and PD,[7–10] but the
study of such species has remained challenging, as they tend
to be low in abundance and adopt a wide range of heteroge-
neous structures. To overcome this problem, we have devel-
oped an array of single-molecule techniques[11–14] to observe
oligomeric species individually, and have applied them to char-
acterise the aggregation pathway of several disease-related
proteins in vitro. In many such methodologies, the protein of
interest needs to be tagged with either an organic fluorophore
or a fluorescent protein. This is very challenging for in vivo or
in cell imaging, and in some cases the label can have an ad-
verse effect on the behaviour of the protein.[15] Alternatively,
dyes such as thioflavin-T/S (ThT/S) or the pentameric form of
formyl thiophene acetic acid (pFTAA), whose fluorescence in
each case is enhanced upon binding to amyloid structures, can
be used to detect protein aggregates. We have recently used
such dyes in combination with total internal reflection fluores-
cence (TIRF) microscopy to image individual aggregates in
human cerebrospinal fluid (CSF) in a diffraction-limited
manner.[16] Such dyes, however, bind to other cellular compo-
nents, thus limiting their versatility,[17] and might not be sensi-
tive to the smaller oligomers that, in addition to being major
therapeutic targets, could also be biomarkers for neurodegen-
eration.[16,18] Furthermore, conventional far-field microscopy
techniques face a limit in the resolving capability imposed by
the optical diffraction barrier. As many subcellular structures
are known to be affected by toxic protein aggregates,[19,20] it is
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important to define the morphology and location of aggre-
gates in the cellular milieu in order to understand the interplay
between protein aggregation and the loss of cellular homeo-
stasis.
We have used an aptamer previously reported to recognise
oligomers and fibrils formed from aS and Ab[21] to enable the
sensitive and specific visualisation of protein aggregates at the
nanoscale. Aptamers are single-stranded oligonucleotides de-
veloped to have high affinity and specificity and can be made
for almost any molecule or structure.[22,23] The advent of super-
resolution (SR) microscopy[24] has improved optical methods.
Recently, an SR method, referred to as DNA PAINT (point accu-
mulation in nanoscale topography), has been developed.[25,26]
The technique uses short complementary strands of DNA: a
“docking” strand is conjugated to an antibody or a protein of
interest, whilst its complementary “imaging” strand is labelled
with an organic fluorophore. We extended the aptamer se-
quence with a docking strand sequence (Figure 1A, Table S1 in
the Supporting Information) to generate SR images of protein
aggregates (Figure 1D); we refer to this method as aptamer
DNA PAINT (ADPAINT). Repeated transient binding of the imag-
ing strands to the docking strand (Figure 1A–C) allows the
labelled biomolecule to be spatially localised and enables the
reconstruction of an SR image. Additional burst montages are
shown in Figure S2 and provide a more complete view of the
variation in fluorescent bursts caused by the stochastic binding
of the imaging strands to the docking strand. DNA PAINT
works with both TIRF microscopy and, more recently, spinning-
disk confocal microscopy.[27] Examples of both aS and Ab oligo-
mers and fibrils imaged by using ADPAINT are shown in Fig-
ure 1D (full fields of view are shown in Figures S3 and S4). A
control experiment on just the imaging strand (without apta-
mer) showed little nonspecific binding of the imaging strands
to the aggregates (Figure S5). The aptamer is specific to the
conformation of the aggregates, so these can be detected
even amongst an excess of monomers. Furthermore, for pri-
mary and secondary antibodies, the size of a probe
can add a linkage error of 15 nm,[28] whereas the
small size of aptamers enables them to bind at a
higher density and at closer proximity to their epi-
topes; this leads to a higher imaging resolution, as
has also been shown with DNA PAINT and non-anti-
body binding proteins such as affimers.[29] Typically,
we achieve a localisation precision of &10 nm
and a resolution of &25 nm (Table S2), with a limit
of detection of &30 pm of aggregates (see the Sup-
porting Information). This enables us to quantify the
oligomers formed during physiologically relevant
aggregation reactions. Each image was acquired
over 200 s; however, as PAINT-based techniques
are not limited by photobleaching,[30] this time can
be lengthened to localise a greater number of bind-
ing events in order to obtain a higher-resolution
image of the protein or the cellular structure of in-
terest.
To assess the ability of ADPAINT to study the het-
erogeneity of complex aggregation mixtures, a solu-
tion of monomeric aS was incubated under condi-
tions previously found to result in its aggrega-
tion.[7, 11] At early time points in the reaction, only a
few aggregates were detected, and these were pre-
dominantly small (<400 nm in length for the first
6 h) and rounded; this is consistent with the expect-
ed appearance of oligomers (Figure 2A). After 10 h,
fibrils were detected. To visualise the distribution of
binding sites within each aggregate, we colour-
coded the localisations according to their local (typi-
cally within 40–50 nm) molecular density. The result-
ing images show maps of the local molecular densi-
ty of individual aptamer binding sites, which reveal
a highly non-uniform distribution, particularly in the
later aggregates (right panel in each case). This
shows that the aggregate structure is not homoge-
neous, but instead varies at the nanoscale, a finding
that is made possible by this method. Further analy-
Figure 1. The concept of ADPAINT. A) Schematic representation of ADPAINT showing an
aggregate bound by multiple aptamers. The DNA docking strand on the aptamer is tran-
siently bound by the complementary imaging strand to generate a SR image. B) Example
time montage of an oligomer undergoing ADPAINT. Each sub-image is separated by
0.5 s, moving through time from left to right then top to bottom; scale bar: 1 mm. C) In-
tensity profile of the oligomer in (B). Each intensity burst represents the binding of the
imaging strand to the aptamer. Grey: raw intensity profile, blue: using a Chung–Kennedy
filter[31] with a window of five frames applied. D) Examples of diffraction-limited (DL,
using thioflavin-T) and super-resolved (using ADPAINT) images of an aS and Ab oligomer
and fibril. Scale bar: 500 nm.
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sis of the ADPAINT images showed that the number of aggre-
gates increased over time; this is consistent with the high ag-
gregation propensity of aS (Figure 2B). Unlike antibodies in
which stoichiometric labelling can be challenging, each apta-
mer is labelled with a single DNA docking strand, thus allowing
quantitative imaging. We took advantage of this by quantify-
ing the number of localisations per aggregate and found that
this increased over time (Figures 2C and S6). Additionally, the
Figure 2. ADPAINT enables the imaging of a range of species formed during the aggregation of aS. A) Example aggregates are shown in SR on the left, with
their corresponding nearest neighbour (NN) plots shown on the right, highlighting hotspots of localisation density. Scale bar: 200 nm. B) The number of ag-
gregates increases over time, and C) the number of localisations also increases as the species get larger; this is shown by D) the mean length increases. Data
shown are mean:SD of three independent aggregation reactions. E) The percentage of liposomes permeabilised upon addition of aggregates from the dif-
ferent time-points (mean:SD over 16 fields of view (69V69 mm)).
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aggregates also became larger, as indicated by the increase in
their mean length (Figures 2D and S7).
The permeabilisation of membranes has been suggested to
be the most ubiquitous toxic mechanism associated with pro-
tein aggregates.[31–35] We have developed a method to charac-
terise the ability of protein aggregates to permeabilise lipid
membranes[8] (details are given in the Supporting Information)
and applied it in this study. We found that the earlier aggre-
gates caused a higher level of influx than those present at
later stages of the aggregation process (those around 600 nm
in length; Figure 2E). Additionally, the binding of the aptamer
to the aggregates did not inhibit their ability to permeabilise
the lipid membranes, and the aptamer itself displayed no pro-
pensity to alter these membranes (Figure S8). Thus, it appears
likely that ADPAINT can be applied to characterise the struc-
tures of the pathological aggregates without altering the func-
tional states of the protein or the cell membrane.
We next used ADPAINT to investigate aggregate formation in a cel-
lular model of PD. Mis-sense mutations[13,36–40] and duplications or
triplications of the SNCA gene, which encodes aS, lead to autoso-
mal dominant early onset PD.[41,42] It has previously been shown
that the formation of aS oligomers in vitro is concentration depen-
dent,[12] and ADPAINT now enables us to determine whether this
dependence is reflected in cellular models that overexpress aS. We
used induced pluripotent stem cells (iPSCs) from a PD patient with
a triplication of the SNCA gene and from a healthy control un-
affected by the disease to generate cortical neurons. Although SR
methods have been used to image fibrils in cells, these are typical-
ly exogenously added aggregates generated from fluorophore-la-
belled protein.[28, 43–47] This is the first case in which a specific probe
for aggregates has been used, and it enables the SR imaging of
unlabelled, endogenous aberrant protein complexes. These were
imaged in fixed, permeabilised cells by using both ADPAINT at the
SR level and in a diffraction-limited manner by using pFTAA, a
green dye that recognises b-sheet structures and becomes fluores-
cent upon binding to protein aggregates.[48,49] To image at a great-
er depth into the cells, the illumination was changed from TIRF to
oblique-angle epifluorescence. Figure 3 shows examples of human
iPSC-derived neurons with and without the SNCA triplication after
they have been plated and stained with pFTAA (further examples
are shown in Figure S9). PFTAA not only binds to the aggregates,
which appear as brighter spots, but also interacts with cellular or-
ganelles and membranes, thereby preventing the aggregates from
being identified or their precise location within the cell from being
determined. Unlike pFTAA, the aptamer has a high specificity, and
only small clusters of binding events are detected within the cyto-
sol. Due to the background fluorescence being higher in oblique-
angle epifluorescence than in TIRF, the resolution we achieved
within cells was lower than the resolution achieved for the aggre-
gates formed in vitro (Table S2). Quantification of these images
shows that there are significantly (p<0.0001) more aggregates in
the cells derived from the individual carrying a triplication of the
SNCA locus compared to iPSC-derived neurons from the healthy
control. We found that the species detected in these experiments
resemble those formed early on in the in vitro aggregation path-
way (0–2 h) shown in Figure 2, having &45 localisations per aggre-
gate (Figure 3C), and being <150 nm in length (Figure 3D). Fur-
thermore, the aggregates detected in the cells having the SNCA
triplication locus give rise to significantly more localisations (Fig-
ure 3C) and are larger (Figure 3D) than those in the healthy con-
trol cells. Given the likelihood of toxicity arising directly from these
aggregates, this observation could help explain the neuronal cell
death associated with PD.
Figure 3. ADPAINT in iPSCs. A) iPSCs from a PD patient with a triplication of
the SNCA gene and from a healthy control. Protein aggregates were imaged
by using pFTAA (green) or ADPAINT (red). Scale bars : 5 mm (top) and 100 nm
(middle). Compared to control cells, SNCA triplication cells show B) signifi-
cantly more aggregates and increases in C) the number of localisations and
D) the average length of the aggregates. The data shown are means:SD of
at least 27 fields of view. *p<0.05, **p<0.001, ***p<0.0001; analysed by t-
test.
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One of the significant advantages of ADPAINT is the ability
of the aptamer to selectively bind to protein aggregates but
not the excess of monomeric protein that is present in cells. As
a comparison, we used the commercially available MJF14-6-4-2
filament antibody, which detects an epitope that is only acces-
sible in aggregates but not in the monomeric protein,[50] and
an Alexa Fluor 405–labelled aptamer to detect dual-labelled
aggregates of aS added to iPSC-derived neurons (Figure S10).
In the case of the MJF14-6-4-2 antibody, there was nonspecific
staining of regions of the cell that did not contain aggregated
aS, whereas the aptamer only detected dual-labelled aggre-
gates. Furthermore, the larger size of antibodies can add a fur-
ther 10–15 nm between the target and the labelled probe.[28]
When used with DNA PAINT, the same MJF14-6-4-2 antibody
(Figure S11), was unable to resolve individual aggregates, but
instead there was diffuse staining in both the SNCA triplication
and control cells.
In conclusion, we have developed an SR method to charac-
terise the toxic species formed during neurodegenerative dis-
eases. We have used ADPAINT to characterise both in vitro ag-
gregates aS and Ab, as well as endogenous unlabelled oligo-
mers formed in patient-derived neurons. Interestingly, we
found that the aggregates formed early on in the in vitro
aggregation closely resemble the morphology of those found
within human iPSC-derived cortical neurons and that these
appear to be most responsible for disrupting lipid membranes.
Although only one stage in the lifetime of the iPSC-derived
cortical neurons was imaged, this method can also be used to
determine how such species develop as cells age, potentially
yielding further insights into the progression of neurodegener-
ative diseases.
Acknowledgements
M.H.H. was supported by a Junior Research Fellowship at Christ’s
College, University of Cambridge, and the Herchel Smith Founda-
tion. Y.Z. was supported by the Cambridge Trust and the Chinese
Scholarship Council. P.F. was supported by Boehringer Ingelheim
Fonds, and the German National Merit Foundation. S.D. is
funded by a Marie-Curie Individual Fellowship. C.M.D. is support-
ed by the Biotechnology and Biochemical Sciences Research
Council and the Wellcome Trust. This work was also supported
by the Cambridge Centre for Misfolding Diseases (P.F. , and
C.M.D.), the Royal Society (D.K.), the European Research Council
with an ERC Advanced Grant (669237; D.R.W and D.K.), and the
Allen Distinguished Investigator Program, through The Paul G.
Allen Frontiers Group (M.H.H.). M.G.S. and L.C. were supported by
the Cambridge Biomedical Research Centre at Addenbrooke’s
Hospital, Cambridge and the Allen Foundation. The authors wish
to thank Swapan Preet for purification of protein, and the
mechanical workshops within the Department of Chemistry for
aiding in the construction of single-molecule instrumentation.
Conflict of Interest
The authors declare no conflict of interest.
Keywords: amyloid formation · aptamers · DNA PAINT ·
induced pluripotent stem cells · neurodegenerative disorders ·
alpha-synuclein
[1] F. Chiti, C. M. Dobson, Annu. Rev. Biochem. 2006, 75, 333–366.
[2] S. Barghorn, P. Davies, E. Mandelkow, Biochemistry 2004, 43, 1694–
1703.
[3] M. G. Spillantini, M. L. Schmidt, V. M.-Y. Lee, J. Q. Trojanowski, R. Jakes,
M. Goedert, Nature 1997, 388, 839–840.
[4] P. J. Barrett, J. T. Greenamyre, Brain Res. 2015, 1628, 247–253.
[5] H. Vicente Miranda, P. M. Szego, L. M. A. Oliveira, C. Breda, E. Darende-
lioglu, R. M. de Oliveira, D. G. Ferreira, M. A. Gomes, R. Rott, M. Oliveira,
et al. , Brain 2017, 140, 1399–1419.
[6] A. Oueslati, M. Fournier, H. A. Lashuel, Prog. Brain Res. 2010, 183, 115–
145.
[7] N. Cremades, S. I. A. Cohen, E. Deas, A. Y. Abramov, A. Y. Chen, A. Orte,
M. Sandal, R. W. Clarke, P. Dunne, F. A. Aprile, C. W. Bertoncini, N. W.
Wood, T. P. J. Knowles, C. M. Dobson, D. Klenerman, Cell 2012, 149,
1048–1059.
[8] P. Flagmeier, S. De, D. C. Wirthensohn, S. F. Lee, C. Vincke, S. Muylder-
mans, T. P. J. Knowles, S. Gandhi, C. M. Dobson, D. Klenerman, Angew.
Chem. Int. Ed. 2017, 56, 7750–7754; Angew. Chem. 2017, 129, 7858–
7862.
[9] L. M. Billings, S. Oddo, K. N. Green, J. L. McGaugh, F. M. LaFerla, Neuron
2005, 45, 675–688.
[10] R. M. Koffie, M. Meyer-Luehmann, T. Hashimoto, K. W. Adams, M. L.
Mielke, M. Garcia-Alloza, K. D. Micheva, S. J. Smith, M. L. Kim, V. M. Lee,
B. T. Hyman, T. L. Spires-Jones, Proc. Natl. Acad. Sci. USA 2009, 106,
4012–4017.
[11] M. H. Horrocks, L. Tosatto, A. J. Dear, G. A. Garcia, M. Iljina, N. Cremades,
M. Dalla Serra, T. P. J. Knowles, C. M. Dobson, D. Klenerman, Anal. Chem.
2015, 87, 8818–8826.
[12] M. Iljina, G. A. Garcia, M. H. Horrocks, L. Tosatto, M. L. Choi, K. A. Gan-
zinger, A. Y. Abramov, S. Gandhi, N. W. Wood, N. Cremades, C. M.
Dobson, T. P. J. Knowles, D. Klenerman, Proc. Natl. Acad. Sci. 2016, 113,
E1206–E1215.
[13] L. Tosatto, M. H. Horrocks, A. J. Dear, T. P. J. Knowles, M. Dalla Serra, N.
Cremades, C. M. Dobson, D. Klenerman, Sci. Rep. 2015, 5, 16696.
[14] S. L. Shammas, G. A. Garcia, S. Kumar, M. Kjaergaard, M. H. Horrocks, N.
Shivji, E. Mandelkow, T. P. J. Knowles, E. Mandelkow, D. Klenerman, Nat.
Commun. 2015, 6, 7025.
[15] V. L. Anderson, W. W. Webb, BMC Biotechnol. 2011, 11, 125.
[16] M. H. Horrocks, S. F. Lee, S. Gandhi, N. K. Magdalinou, S. W. Chen, M. J.
Devine, L. Tosatto, M. Kjaergaard, J. S. Beckwith, H. Zetterberg, et al. ,
ACS Chem. Neurosci. 2016, 7, 399–406.
[17] S. Sugimoto, K. Arita-Morioka, Y. Mizunoe, K. Yamanaka, T. Ogura, Nucle-
ic Acids Res. 2015, 43, e92–e92.
[18] T. Tokuda, M. M. Qureshi, M. T. Ardah, S. Varghese, S. A. S. Shehab, T.
Kasai, N. Ishigami, A. Tamaoka, M. Nakagawa, O. M. A. El-Agnaf, Neurolo-
gy 2010, 75, 1766–1772.
[19] D. Snead, D. Eliezer, Exp. Neurobiol. 2014, 23, 292–313.
[20] L. Ruan, C. Zhou, E. Jin, A. Kucharavy, Y. Zhang, Z. Wen, L. Florens, R. Li,
Nature 2017, 543, 443–446.
[21] K. Tsukakoshi, K. Abe, K. Sode, K. Ikebukuro, Anal. Chem. 2012, 84,
5542–5547.
[22] C. Tuerk, L. Gold, Science 1990, 249, 505–510.
[23] A. D. Ellington, J. W. Szostak, Nature 1990, 346, 818–822.
[24] M. H. Horrocks, M. Palayret, D. Klenerman, S. F. Lee, Histochem. Cell Biol.
2014, 141, 577–585.
[25] R. Jungmann, C. Steinhauer, M. Scheible, A. Kuzyk, P. Tinnefeld, F. C.
Simmel, Nano Lett. 2010, 10, 4756–4761.
[26] R. Jungmann, M. S. AvendaÇo, J. B. Woehrstein, M. Dai, W. M. Shih, P.
Yin, Nat. Methods 2014, 11, 313–318.
[27] F. Schueder, J. Lara-Guti8rrez, B. J. Beliveau, S. K. Saka, H. M. Sasaki, J. B.
Woehrstein, M. T. Strauss, H. Grabmayr, P. Yin, R. Jungmann, Nat.
Commun. 2017, 8, 2090.
[28] S. J. Sahl, L. E. Weiss, W. C. Duim, J. Frydman, W. E. Moerner, Sci. Rep.
2012, 2, 895.
ChemBioChem 2018, 19, 2033 – 2038 www.chembiochem.org T 2018 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim2037
Communications
[29] T. Schlichthaerle, A. S. Eklund, F. Schueder, M. T. Strauss, C. Tiede, A.
Curd, J. Ries, M. Peckham, D. C. Tomlinson, R. Jungmann, Angew. Chem.
Int. Ed. 2018, 57, 11060; Angew. Chem. 2018, 130, 11226.
[30] A. Sharonov, R. M. Hochstrasser, Proc. Natl. Acad. Sci. USA 2006, 103,
18911–18916.
[31] C. Soto, Nat. Rev. Neurosci. 2003, 4, 49–60.
[32] C. Haass, D. J. Selkoe, Nat. Rev. Mol. Cell Biol. 2007, 8, 101–112.
[33] I. Benilova, E. Karran, B. De Strooper, Nat. Neurosci. 2012, 15, 349–357.
[34] M. Andreasen, N. Lorenzen, D. Otzen, Biochim. Biophys. Acta Biomembr.
2015, 1848, 1897–1907.
[35] M. Serra-Batiste, M. Ninot-Pedrosa, M. Bayoumi, M. Gair&, G. Maglia, N.
Carulla, Proc. Natl. Acad. Sci. USA 2016, 113, 10866–10871.
[36] J. J. Zarranz, J. Alegre, J. C. Gjmez-Esteban, E. Lezcano, R. Ros, I. Am-
puero, L. Vidal, J. Hoenicka, O. Rodriguez, B. Atar8s, V. Llorens, E. Gomez
Tortosa, T. del Ser, D. G. MuÇoz, J. G. de Yebenes, Ann. Neurol. 2004, 55,
164–173.
[37] S. Lesage, M. Anheim, F. Letournel, L. Bousset, A. Honor8, N. Rozas, L.
Pieri, K. Madiona, A. Derr, R. Melki, C. Verny, A. Brice, Ann. Neurol. 2013,
73, 459–471.
[38] P. Flagmeier, G. Meisl, M. Vendruscolo, T. P. J. Knowles, C. M. Dobson,
A. K. Buell, C. Galvagnion, Proc. Natl. Acad. Sci. USA 2016, 113, 10328–
10333.
[39] M. H. Polymeropoulos, C. Lavedan, E. Leroy, S. E. Ide, A. Dehejia, A.
Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E. S. Stenroos, S. Chan-
drasekharappa, A. Athanassiadou, Th. Papapetropoulos, W. G. Johnson,
A. M. Lazzarini, R. C. Duvoisin, G. Di Iorio, L. I. Golbe, R. L. Nussbaum, Sci-
ence 1997, 276, 2045–2047.
[40] R. Kreger, W. Kuhn, T. Meller, D. Woitalla, M. Graeber, S. Kçsel, H. Przun-
tek, J. T. Epplen, L. Schçls, O. Riess, Nat. Genet. 1998, 18, 106–108.
[41] M.-C. Chartier-Harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay, S.
Lincoln, C. Levecque, L. Larvor, J. Andrieux, M. Hulihan, N. Waucquier, L.
Defebvre, P. Amouyel, M. Farrer, A. Dest8e, Lancet Lond. Engl. 2004, 364,
1167–1169.
[42] A. B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kacher-
gus, M. Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, et al. , Science
2003, 302, 841.
[43] G. S. Kaminski Schierle, S. van de Linde, M. Erdelyi, E. K. Esbjçrner, T.
Klein, E. Rees, C. W. Bertoncini, C. M. Dobson, M. Sauer, C. F. Kaminski, J.
Am. Chem. Soc. 2011, 133, 12902–12905.
[44] E. K. Esbjçrner, F. Chan, E. Rees, M. Erdelyi, L. M. Luheshi, C. W. Bertonci-
ni, C. F. Kaminski, C. M. Dobson, G. S. Kaminski Schierle, Chem. Biol.
2014, 21, 732–742.
[45] M. J. Roberti, J. Fçlling, M. S. Celej, M. Bossi, T. M. Jovin, E. A. Jares-Erij-
man, Biophys. J. 2012, 102, 1598–1607.
[46] M. M. Apetri, R. Harkes, V. Subramaniam, G. W. Canters, T. Schmidt, T. J.
Aartsma, PLoS One 2016, 11, e0153020.
[47] D. Pinotsi, C. H. Michel, A. K. Buell, R. F. Laine, P. Mahou, C. M. Dobson,
C. F. Kaminski, G. S. Kaminski Schierle, Proc. Natl. Acad. Sci. USA 2016,
113, 3815–3819.
[48] J. Brelstaff, M. G. Spillantini, A. M. Tolkovsky, Neural Regen. Res. 2015, 10,
1746–1747.
[49] J. Brelstaff, B. Ossola, J. J. Neher, T. Klingstedt, K. P. R. Nilsson, M. Goe-
dert, M. G. Spillantini, A. M. Tolkovsky, Front. Neurosci. 2015, 9, 184.
[50] L. B. Lassen, E. Gregersen, A. K. Isager, C. Betzer, R. H. Kofoed, P. H.
Jensen, PLoS One 2018, 13, e0196056.
Manuscript received: April 21, 2018
Revised manuscript received: July 8, 2018
Accepted manuscript online: July 27, 2018
Version of record online: September 11, 2018
ChemBioChem 2018, 19, 2033 – 2038 www.chembiochem.org T 2018 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim2038
Communications
